May 16 |
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
|
May 15 |
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
|
May 10 |
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript
|
May 10 |
Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript
|
May 9 |
Oncolytics Biotech GAAP EPS of -$0.09 misses by $0.01
|
May 9 |
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
|
May 9 |
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
|
May 8 |
Oncolytics Biotech Q1 2024 Earnings Preview
|
May 8 |
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
|
Apr 30 |
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
|